Motus GI

Colon Cleansing for Colonoscopy

Health Tech & Life Sciences
Public on NASDAQ on Feb, 2018<br>

Company Overview

Snapshot

Founded in October 2008, Motus GI operates with 11–50 employees. The company has raised a total of $64.5 million across 5 funding rounds from 9 investors. Motus GI became public on NASDAQ in February 2018.

Business overview

Motus GI is a medical technology company focused on enhancing endoscopy outcomes and patient experiences. Its core product, the Pure-Vu System, is designed to improve colonoscopy procedures by effectively cleaning poorly prepped colons during the examination. This system aims to reduce reliance on extensive pre-procedural preparations, thereby improving the quality and cost-effectiveness of colonoscopies for early detection and prevention of colorectal cancer. The company operates within the Health Tech & Life Sciences sector, specifically targeting healthcare providers in the medical devices and diagnostics devices markets.

Strategic signal

In October 2023, Motus GI received FDA clearance to commercialize its Pure-Vu EVS Gastro and Gen 4 Colon systems. This regulatory approval is a significant validation of the company's technology, enabling broader market access for its advanced colon cleansing solutions. For investors, this signals continued product innovation and potential for increased revenue streams in the medical device market, reinforcing Motus GI's position in improving gastrointestinal diagnostic procedures.

Company Intelligence Q&A

What was a key regulatory milestone for Motus GI in late 2023?
In October 2023, Motus GI received FDA clearance to commercialize its Pure-Vu EVS Gastro and Gen 4 Colon systems, expanding its product offerings for gastrointestinal procedures.
What strategic board appointment did Motus GI make in September 2023?
In September 2023, Motus GI appointed medical device industry veteran Scott Durbin to its Board of Directors, strengthening its leadership with experienced industry expertise.
What significant product submission did Motus GI make to the FDA in September 2023?
In September 2023, Motus GI submitted a Special 510(k) to the FDA for its Pure-Vu EVS Gen 4 Gastro and Colon systems, indicating ongoing product development and regulatory engagement.
When did Motus GI complete its first upper GI patient procedure for the Pure-Vu EVS Gastro?
In November 2023, Motus GI announced the completion of its first upper GI patient procedure for the FDA-cleared Pure-Vu EVS Gastro system, marking a clinical milestone for the device.
What was a notable financial event for Motus GI in May 2023?
In May 2023, Motus GI announced a $3.5 million private placement, priced at-the-market under Nasdaq rules, to support its operations and growth initiatives.

External links